Marc Wolfgang, M.S.
Head of CMC
Senda Biosciences

Mr. Wolfgang is a senior executive with more than 25 years of experience in the biophar­ma­ceu­tical industry and deep expertise across manufacturing, process and analytical development, QA/QC, regulatory affairs, and program/​portfolio management. He joins Senda from BioNTech US, where he served as Vice President, U.S. Manufacturing, with responsibility for the manufacturing and supply chain of U.S.-based cell and gene therapy products (CAR‑T and modified T‑Cell products), including outsourcing and internal manufacture. Mr. Wolfgang had previously served as Vice President, Technical Operations for Neon Therapeutics (prior to acquisition by BioNTech), where he was responsible for the manufacturing, supply operations, and quality control of personalized peptide vaccine and oncology T‑Cell products. 

Before Neon, Mr. Wolfgang served as VP Technical Operations at Cerulean Pharma, where he was responsible for CMC strategy and operations for two nano-pharmaceutical platforms in the oncology space. Prior to that, he served in a series of increasingly senior leadership positions at Momenta Pharmaceuticals, Millennium Pharmaceuticals, and Biogen. He also served as chairman in 2016 and as a board member from 2011 to 2016 of the Nanomedicines Alliance, a Washington D.C. cooperative advocating for the development and commer­cial­iza­tion of nanomedicine therapies. He holds an M.S. in chemistry from Montclair State University and a B.S. in biology from Pennsylvania State University.